544 / 1631
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in
first-line treatment of indolent NHL or MCL: the BRIGHT study.
Overall Response
BR
R-CHOP/R-CVP
Overall Response Rate
97%
91%
Complete Response
31%
25%
Partial Response
65%
66%
Flinn, I. et al
Blood. 2014 May 8;123(19):2944-52.
Toxicity
BR
R-CHOP
R-CVP
Vomiting
25-29%
13%
13%%
Infections (Gr3+)
7-12%
5%
7%
Rash
12-18%
7%
9%
Neuropathy
4%
20%
26%
Alopecia
4%
51%
21%
Neutropenia (Gr3+)
39-49%
86%
56%
Lymphopenia (Gr3+)
61-63%
33%
28%
Platelets (Gr3+)
5-10%
12%
2%
Efficacy
Toxicity